2023
DOI: 10.1002/cyto.a.24716
|View full text |Cite
|
Sign up to set email alerts
|

Immunophenotypical profiling of myeloid neoplasms with erythroid predominance using mass cytometry (CyTOF)

Abstract: Acute erythroid leukemia (AEL) is a disease continuum between Myelodysplastic syndrome (MDS) and Acute myeloid leukemia (AML) with the cellular hallmark of uncontrolled proliferation and impaired differentiation of erythroid progenitor cells. First described by Giovanni di Guglielmo in 1917 AEL accounts for less than 5% of all de novo AML cases. There have been efforts to characterize AEL at a molecular level, describing recurrent alterations in TP53, NPM1 and FLT3 genes. A genomic analysis of AEL cases confir… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
4
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
4

Relationship

0
4

Authors

Journals

citations
Cited by 4 publications
(4 citation statements)
references
References 32 publications
(57 reference statements)
0
4
0
Order By: Relevance
“…The availability of new technologies such as CyTOF mass spectrometry and full-spectrum flow cytometry (FSFC) has demonstrated the capacity to utilize many markers (up to 27 colors) for AML MRD. 84 85 Additionally, by increasing the number of events from 1 million to 10 million, the sensitivity of MRD assay can easily be reached to as high as 2 × 10 −6 (0.0002%) MRD detection. 63 Thus, the recent availability of new flow cytometry technologies and newer dyes has improved the assay sensitivity and specificity for MRD assessment by flow cytometry.…”
Section: Discussionmentioning
confidence: 99%
“…The availability of new technologies such as CyTOF mass spectrometry and full-spectrum flow cytometry (FSFC) has demonstrated the capacity to utilize many markers (up to 27 colors) for AML MRD. 84 85 Additionally, by increasing the number of events from 1 million to 10 million, the sensitivity of MRD assay can easily be reached to as high as 2 × 10 −6 (0.0002%) MRD detection. 63 Thus, the recent availability of new flow cytometry technologies and newer dyes has improved the assay sensitivity and specificity for MRD assessment by flow cytometry.…”
Section: Discussionmentioning
confidence: 99%
“…Although it has not been demonstrated yet, a comparable mechanism may occur in neoplastic erythroblastic islands. As illustrated in this case, MDS and AEL are recognised as part of a disease continuum and increased CD47 expression has been observed in both myeloblasts and erythroblasts [2]. Therefore, anti‐CD47 immunotherapy should be a therapeutic option to consider in cases of AEL and MDS with increased dysplastic erythroid lineage.…”
Section: Figurementioning
confidence: 93%
“…The feasibility, applicability, and prognostic effect of MFC‐MRD testing in lower‐intensity regimens have already been demonstrated ( Recommendation 1 ) 12,13 . However, the development of novel assays such NGS, digital droplet PCR, single‐cell sequencing, and highly multiplexed immunophenotyping (e.g., mass cytometry and Cytof) 28 is providing us with new avenues for detection and monitoring MRD as well as enabling us to better understand the biology of MRD. For the time being, technical recommendations provided in the ELN‐MRD guideline for MRD assessment by MFC‐MRD and molecular MRD apply also to patients treated with lower‐intensity regimens ( Recommendation 2 ) 24 .…”
Section: Recommendations For Assay Selectionmentioning
confidence: 99%
“…25 The feasibility, applicability, and prognostic effect of MFC-MRD testing in lower-intensity regimens have already been demonstrated (Recommendation 1). 12,13 However, the development of novel assays such NGS, digital droplet PCR, single-cell sequencing, and highly multiplexed immunophenotyping (e.g., mass cytometry and Cytof) 28 aberrations. This has already been used extensively in intensive regimens but may also be applicable to patients treated with lowerintensity regimens.…”
Section: Recommendations For Assay Selectionmentioning
confidence: 99%